Author
Listed:
- Monir Ejemel
(MassBiologics of the University of Massachusetts Medical School)
- Qi Li
(MassBiologics of the University of Massachusetts Medical School)
- Shurong Hou
(University of Massachusetts Medical School)
- Zachary A. Schiller
(MassBiologics of the University of Massachusetts Medical School)
- Julia A. Tree
(Public Health England, Porton Down)
- Aaron Wallace
(MassBiologics of the University of Massachusetts Medical School)
- Alla Amcheslavsky
(MassBiologics of the University of Massachusetts Medical School)
- Nese Kurt Yilmaz
(University of Massachusetts Medical School)
- Karen R. Buttigieg
(Public Health England, Porton Down)
- Michael J. Elmore
(Public Health England, Porton Down)
- Kerry Godwin
(Public Health England, Porton Down)
- Naomi Coombes
(Public Health England, Porton Down)
- Jacqueline R. Toomey
(MassBiologics of the University of Massachusetts Medical School)
- Ryan Schneider
(MassBiologics of the University of Massachusetts Medical School)
- Anudeep S. Ramchetty
(MassBiologics of the University of Massachusetts Medical School)
- Brianna J. Close
(Boston University)
- Da-Yuan Chen
(Boston University)
- Hasahn L. Conway
(Boston University)
- Mohsan Saeed
(Boston University)
- Chandrashekar Ganesa
(MassBiologics of the University of Massachusetts Medical School)
- Miles W. Carroll
(Public Health England, Porton Down)
- Lisa A. Cavacini
(MassBiologics of the University of Massachusetts Medical School)
- Mark S. Klempner
(MassBiologics of the University of Massachusetts Medical School)
- Celia A. Schiffer
(University of Massachusetts Medical School)
- Yang Wang
(MassBiologics of the University of Massachusetts Medical School)
Abstract
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks ACE2 receptor binding, by overlapping the ACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells expressing ACE2. When converted to secretory IgA, MAb326 also neutralizes authentic SARS-CoV-2 virus while the IgG isotype shows no neutralization. Our results suggest that SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.
Suggested Citation
Monir Ejemel & Qi Li & Shurong Hou & Zachary A. Schiller & Julia A. Tree & Aaron Wallace & Alla Amcheslavsky & Nese Kurt Yilmaz & Karen R. Buttigieg & Michael J. Elmore & Kerry Godwin & Naomi Coombes , 2020.
"A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction,"
Nature Communications, Nature, vol. 11(1), pages 1-9, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18058-8
DOI: 10.1038/s41467-020-18058-8
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Karla P. Garcia-Pelagio & Tamara Hew-Butler & Mariane M. Fahlman & Joseph A. Roche, 2021.
"Women’s Lives Matter—The Critical Need for Women to Prioritize Optimal Physical Activity to Reduce COVID-19 Illness Risk and Severity,"
IJERPH, MDPI, vol. 18(19), pages 1-20, September.
- Zhenzhen Wang & Shiqi Hu & Kristen D. Popowski & Shuo Liu & Dashuai Zhu & Xuan Mei & Junlang Li & Yilan Hu & Phuong-Uyen C. Dinh & Xiaojie Wang & Ke Cheng, 2024.
"Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2,"
Nature Communications, Nature, vol. 15(1), pages 1-15, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18058-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.